By Fineline Cube 
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version of Japan-based Santen Pharmaceutical Co., Ltd’s Diquas (diquafosol) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step toward expanding treatment options for dry eye patients in China.
Diquafosol Mechanism
Diquafosol is an ophthalmic solution that stimulates tear and mucin secretion, addressing key symptoms of dry eye disease. It also improves corneal epithelial damage, providing comprehensive relief for patients suffering from dry eye conditions.
Market Potential
The acceptance of Uni-Bio Science’s generic version of Diquas for review by the NMPA highlights the company’s commitment to bringing cost-effective and accessible treatments to the market. This move is expected to enhance the availability of therapeutic options for dry eye patients, a condition that affects a significant portion of the population.-Fineline Info & Tech